Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

DCC Q1 operating profits 'modestly behind' prior year

(Sharecast News) - Sales, marketing and support services firm DCC said on Thursday that operating profits in the three months ended June were "modestly behind" the same period a year earlier in the "seasonally less significant first quarter". DCC said its DCC Energy division had traded in line with expectations and was "modestly below" the prior year, while DCC Technology traded in line with the prior year.

Looking ahead, DCC expects FY26 to be "a year of good operating profit growth" on a continuing basis, strategic progress and continued development activity.

Chief executive Donal Murphy said: "Our simplification strategy is progressing to plan. We have reached [an] agreement for the sale of DCC Healthcare, made good progress on the integration of our North American Technology businesses and put our new DCC Leadership Team in place.

"We will continue to grow our customer base by being the provider of choice for essential energy products and by selling more services to our energy customers, driving higher organic growth rates."

As of 0840 BST, DCC shares were down 0.21% at 4,756.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.